dear
isar
member
behalf
offic
board
member
pleas
welcom
everyon
la
jolla
th
intern
confer
antivir
research
wish
highli
success
meet
hope
walk
away
impress
qualiti
scientif
present
new
addit
research
network
gather
la
jolla
deepli
sadden
loss
chri
mcguigan
friend
colleagu
mani
year
chri
pillar
antivir
research
commun
longtim
member
past
presid
isar
mani
other
also
mentor
colleagu
good
friend
mani
accomplish
honor
th
icar
feel
presenc
spirit
work
live
advanc
pioneer
mani
student
scientist
mentor
mani
activ
member
societi
behalf
isar
send
condol
mcguigan
famili
mani
friend
colleagu
tragic
loss
chri
would
wish
cuttingedg
program
la
jolla
offer
great
scienc
allimport
time
network
reconnect
friend
around
world
mark
prichard
program
team
work
hard
attract
top
speaker
also
revamp
abstract
submiss
process
develop
new
workshop
diagnost
technolog
meet
begin
tribut
chri
contribut
scienc
societi
follow
two
keynot
address
first
richard
h
scheuermann
j
craig
venter
institut
explor
avail
wholegenom
sequenc
data
combin
standard
represent
phenotyp
characterist
larg
number
viral
isol
allow
extens
genotypephenotyp
associ
studi
go
well
beyond
tradit
phylogenet
lineag
trace
illustr
concept
focus
two
area
use
statist
genom
analysi
predict
influenza
viru
evolut
face
adapt
immun
identif
novel
genet
determin
diseas
sever
enteroviru
second
keynot
address
heinz
feldmann
niaid
rocki
mountain
laboratori
take
differ
direct
focus
past
present
futur
ebola
viru
heinz
initi
train
research
marburg
germani
site
first
filoviru
outbreak
review
histori
marburg
ebola
virus
discoveri
recent
west
african
epidem
provid
look
ahead
research
need
go
lesson
learn
west
africa
clearli
critic
understand
prevent
widespread
epidem
futur
limit
global
spread
air
travel
also
look
forward
award
lectur
two
distinguish
senior
scientist
promis
younger
investig
doug
richman
uc
san
diego
receiv
gertrud
elion
award
robert
vinc
univers
minnesota
receiv
antonin
award
jerom
deval
alio
biopharma
receiv
prusoff
young
investig
award
present
review
past
accomplish
focus
prioriti
futur
research
high
point
meet
th
icar
also
featur
three
symposia
first
cover
varieti
topic
structur
biolog
becom
import
progress
antivir
research
speaker
san
diegola
jolla
area
includ
clodagh
oshea
salk
institut
prusoff
award
winner
erica
ollman
saphir
scripp
research
institut
second
symposium
examin
import
aspect
zika
viru
spread
rapidli
central
south
america
caus
alarm
associ
fetal
anomali
syndrom
peiyong
shi
lead
overview
zika
relationship
flavivirus
justin
juland
johan
neyt
follow
discuss
anim
model
antivir
vaccin
develop
third
symposium
focu
dna
virus
effect
antivir
therapi
develop
dna
virus
unexpect
genet
variat
includ
discoveri
quasispeci
within
host
highlight
need
new
antivir
combin
therapi
among
speaker
topic
thoma
lion
monitor
adenoviru
infect
paul
lambert
new
approach
papillomaviru
diseas
david
bernstein
current
statu
vaccin
herp
simplex
viru
addit
excel
symposia
diagnost
technolog
workshop
tuesday
afternoon
showcas
new
rapid
method
identifi
viral
infect
ensur
patient
benefit
effect
antivir
therapi
importantli
new
technolog
potenti
maxim
power
clinic
trial
identifi
patient
popul
infect
viru
interest
free
common
infect
could
mask
clinic
respons
workshop
also
highlight
new
techniqu
help
drive
drug
discoveri
process
final
messag
isar
presid
two
year
flown
turn
presid
role
presidentelect
johan
neyt
confid
isar
good
hand
futur
bright
term
presid
focus
increas
membership
new
ambassador
program
explor
way
involv
young
investig
societi
icar
futur
hope
continu
address
goal
essenti
continu
success
wish
everyon
highli
success
enjoy
th
icar
look
forward
meet
everyon
confer
chri
except
bright
medicin
chemist
broad
background
insight
wide
differ
field
human
health
research
best
known
invent
wide
varieti
phosphoramid
protid
optim
intracellular
drug
deliveri
circumv
metabol
bottleneck
activ
nucleosidebas
antivir
anticanc
drug
least
four
compound
base
technolog
enter
clinic
trial
includ
acelarin
phase
iii
evalu
ovarian
cancer
phase
trial
breast
colon
cancer
work
inspir
research
lead
prodrug
tenofovir
alafenamid
sofosbuvir
backbon
drug
singletablet
regimen
transform
therapi
hiv
hcv
infect
chri
also
coinventor
highli
potent
select
antivzv
drug
phosphoramid
prodrug
origin
long
close
collabor
group
rega
institut
ku
leuven
prodrug
current
phase
iii
clinic
trial
also
develop
treatment
hepat
c
reach
phase
ii
trial
pursu
due
unexpect
sideeffect
trial
conjunct
anoth
drug
also
coinvent
new
glucosamin
phosphat
potenti
use
osteoarthr
addit
achiev
chri
outstand
manag
team
scientist
world
quit
demand
extrem
punctual
master
motiv
team
member
annual
laboratori
away
day
phd
candid
postdoc
present
result
futur
plan
alway
invit
foreign
expert
judg
result
amaz
see
student
collabor
inspir
drive
enthusiasm
also
possess
art
teach
entertain
manner
could
explain
scientif
result
potenti
implic
audienc
scientist
nonscientist
like
one
els
career
train
research
includ
phd
student
chri
except
warm
charm
gener
person
profound
social
entertain
abil
often
center
attent
meet
alway
fun
stori
tell
collabor
chri
often
led
close
friendship
enorm
privileg
group
leuven
collabor
mani
year
chri
die
much
young
still
mani
idea
work
mani
respons
directli
impact
advanc
scienc
human
health
owe
deep
gratitud
respect
achiev
unforgett
interact
mani
occas
miss
jan
balzarini
camarasa
anna
karlsson
carlofederico
perno
behalf
research
team
delight
welcom
colleagu
th
icar
la
jolla
pleasur
honor
share
hometown
lead
investig
contribut
excit
dynam
progress
field
remark
list
past
accomplish
hiv
hcv
new
scientif
develop
herpesvirus
respiratori
virus
emerg
global
threat
dengu
chikungunya
zika
ebola
virus
antivir
research
come
long
way
sinc
first
icar
promis
make
critic
import
contribut
next
year
confid
venu
match
excel
program
list
particip
meet
la
jolla
mesa
coloc
mani
major
institut
includ
univers
california
san
diego
scripp
research
institut
salk
institut
sanford
burnham
prebi
medic
discoveri
institut
la
jolla
institut
j
craig
venter
institut
well
larg
number
pharma
biotech
compani
particip
excit
progress
meet
venu
locat
central
mesa
beauti
set
look
forward
interact
hope
enjoy
fulfil
experi
th
icar
la
jolla
th
icar
site
locat
torrey
pine
mesa
home
univers
california
san
diego
scripp
research
institut
salk
institut
sanford
burnham
prebi
medic
discoveri
institut
j
craig
venter
institut
jcvi
recent
addit
area
beauti
new
build
overlook
pacif
fortun
richard
scheuermann
director
informat
jcvi
one
leadoff
speaker
area
also
home
mani
public
trade
biotech
compani
innumer
startup
confer
hotel
hilton
la
jolla
torrey
pine
locat
one
except
set
southern
california
atop
bluff
la
jolla
overlook
legendari
torrey
pine
golf
cours
site
us
open
san
diego
annual
pga
tour
event
nearli
squar
feet
event
meet
space
hotel
provid
set
inspir
reward
entertain
attende
uniqu
san
diego
guestroom
privat
balconi
patio
ocean
garden
golf
cours
view
amen
includ
access
exclus
guarante
daili
tee
time
highli
covet
torrey
pine
golf
cours
guest
privileg
spa
torrey
pine
awardwin
dine
torreyana
grill
experi
feel
seclus
yet
remain
close
everyth
san
diego
offer
explor
stylish
boutiqu
museum
except
cuisin
la
jolla
follow
relax
visit
spa
unwind
besid
pool
enjoy
excit
san
diego
zoo
sea
world
wild
anim
park
well
explor
mile
unspoil
beach
natur
trail
torrey
pine
reserv
la
jolla
mile
south
worldclass
shop
oneofakind
dine
beach
cultur
high
cultur
find
amaz
rang
dine
choic
fine
cuisin
quaint
cafe
renown
restaur
neighborhood
favorit
everi
occas
everi
budget
breakfast
lunch
dinner
perfect
menu
right
around
corner
choic
celebr
bargainhunt
alik
shopper
find
priceless
popular
world
luxuri
brand
everyday
valu
museum
contemporari
art
san
diego
mcasd
region
foremost
forum
devot
explor
present
art
time
present
work
across
media
creat
sinc
locat
coastal
commun
la
jolla
downtown
san
diego
mcasd
showcas
intern
recogn
collect
dynam
schedul
exhibit
del
mar
mile
north
relax
surf
beach
villag
del
mar
less
crowd
mile
excel
familyfriendli
beach
mani
restaur
karl
hostetl
favorit
rusti
surf
shop
jake
restaur
beach
weather
gener
mild
time
april
low
chanc
moder
heavi
rain
want
check
weather
serious
go
http
look
forward
see
april
th
emerg
hiv
earli
laboratori
perform
pioneer
studi
pathogenesi
aid
assess
first
antiretrovir
group
first
identifi
hiv
drug
resist
later
document
impact
resist
treatment
failur
presenc
mixtur
differ
viral
phenotyp
genotyp
patient
preexist
drugresist
mutant
untreat
patient
studi
help
establish
import
drug
resist
assay
daytoday
manag
hiv
infect
doug
team
ucsd
also
join
other
identifi
latent
infect
cell
obstacl
erad
hiv
infect
antiretrovir
therapi
major
area
investig
includ
develop
assay
measur
viral
reservoir
variou
bodi
compart
character
variou
subset
lymphocyt
target
intervent
strategi
effort
reliabl
measur
impact
intervent
research
also
focus
virolog
host
determin
hiv
transmiss
implic
develop
effect
vaccin
develop
antivir
suppress
viru
consequ
transmiss
major
issu
antiretrovir
therapi
resourc
deliveri
treatment
hivinfect
individu
two
critic
challeng
hiv
research
develop
vaccin
peopl
yet
infect
alreadi
infect
need
find
cure
new
opportun
drug
discoveri
two
excit
period
first
involv
clinic
develop
first
antiretrovir
drug
azt
identifi
develop
drugresist
mutant
turn
major
aspect
drug
develop
clinic
manag
second
document
latent
reservoir
obstacl
cure
grown
major
object
current
research
cours
enjoy
meet
old
friend
actual
get
old
meet
new
one
interest
thing
remark
first
went
icar
drug
amantadin
vidarabin
antivir
treat
million
infect
hiv
hbv
cure
million
hcv
obtain
bachelor
degre
pharmaci
suni
buffalo
stay
join
research
group
howard
schaeffer
receiv
phd
medicin
chemistri
studi
synthesi
biochem
activ
acycl
nucleosid
analogu
investig
acycloadenosin
earli
step
road
discoveri
acyclovir
schaeffer
move
burrough
wellcom
began
work
gertrud
elion
bob
join
medicin
chemistri
faculti
univers
minnesota
major
focu
character
carbocycl
nucleosid
analogu
appear
promis
anticanc
antivir
activ
earli
demonstr
carbocycl
arabinofuranosyladenin
cyclaradin
activ
herpesviru
infect
guinea
pig
howev
emerg
hiv
reveal
true
import
compound
carbocycl
dideoxynucleosid
analogu
found
inhibit
revers
transcriptas
initi
seri
compound
dub
carbovir
deriv
parent
compound
molecul
cyclopropyl
group
nitrogen
adenin
ring
becam
known
abacavir
select
commerci
develop
abacavir
prove
rapidli
absorb
gi
tract
good
cn
penetr
although
glaxo
licens
carbovir
abacavir
reach
market
releas
commerci
product
abacavir
relat
molecul
markedli
facilit
bob
develop
bicycl
molecul
compound
known
world
medicin
chemistri
vinc
lactam
conveni
start
point
synthesi
varieti
carbocycl
nucleosid
also
provid
scaffold
therapeut
molecul
glycosidas
inhibitor
royalti
abacavir
enabl
univers
minnesota
establish
center
drug
design
bob
direct
sinc
among
mani
honor
induct
medicin
chemistri
hall
fame
american
chemic
societi
award
honorari
doctor
scienc
degre
alma
mater
sunybuffalo
intern
societi
nucleosid
nucleotid
nucleic
acid
select
imbach
townsend
award
import
challeng
identifi
new
target
drug
design
back
earli
gener
think
nucleosid
analog
good
candid
antivir
agent
would
act
like
anticanc
agent
would
toxic
use
know
today
true
excit
part
career
director
center
drug
design
avail
royalti
fund
develop
ziagen
allow
initi
new
research
project
area
unrel
previous
fund
research
grant
thu
addit
antivir
anticanc
project
establish
program
area
detect
earli
alzheim
diseas
protect
dna
damag
stimul
dna
repair
agent
interferon
stimul
antiag
wound
heal
etc
spend
time
lab
day
research
group
discuss
result
detail
ongo
project
one
lead
candid
novel
nucleosid
analogu
enter
phase
trial
earli
evalu
rsvinfect
adult
hospit
infant
hcv
polymeras
inhibitor
reach
phase
ii
clinic
trial
newest
antihcv
nucleotid
analog
current
test
phase
ii
combin
therapi
jerom
also
member
team
discov
novel
class
influenza
polymeras
inhibitor
one
test
safeti
efficaci
influenza
challeng
studi
jerom
one
jerom
main
respons
alio
develop
vitro
method
identifi
novel
nucleosid
analogu
aim
larg
spectrum
rna
virus
alio
becam
affili
janssen
pharmaceut
divis
johnson
johnson
becam
scientif
director
januari
import
challeng
antivir
research
believ
transit
focu
chronic
acut
viral
infect
repres
import
chang
tough
challeng
way
need
think
drug
discoveri
drug
develop
number
ongo
clinic
studi
firstinclass
drug
candid
soon
inform
us
potenti
effect
treat
acut
viral
infect
hospit
outpati
set
consid
bench
scientist
realli
enjoy
find
time
lab
conduct
experi
exampl
still
get
excit
sd
page
novel
protein
construct
express
purifi
first
time
also
love
experi
test
newli
synthes
molecul
first
biolog
assay
work
environ
bring
togeth
biologist
chemist
scientif
discoveri
translat
new
drug
candid
potenti
save
live
incred
satisfi
also
realli
enjoy
work
virus
effect
therapi
yet
avail
new
laboratori
method
hold
promis
antivir
drug
develop
lot
project
current
involv
limit
abil
produc
larg
amount
function
protein
target
recent
progress
rapid
screen
optim
protein
product
condit
use
modern
molecular
biolog
biochemistri
method
realli
open
new
avenu
drug
discoveri
particularli
true
larg
protein
complex
influenza
rsv
polymeras
combin
recent
breakthrough
crystallographi
advanc
protein
biochemistri
enabl
structurebas
drug
design
method
choic
antivir
research
isar
contribut
career
first
icar
pragu
year
develop
friendship
mani
isar
member
becom
collabor
colleagu
confer
alway
give
opportun
keep
academ
industri
research
directli
relev
work
th
annual
women
scienc
roundtabl
first
event
first
day
icar
held
sunday
april
pm
open
women
men
featur
discuss
challeng
opportun
encount
women
scientist
navig
twist
turn
career
progress
today
environ
kara
carter
lead
discuss
roundtabl
attende
tabl
th
icar
rome
pleas
join
us
network
fellow
scientist
industri
govern
academia
conduct
aspect
antivir
research
roundtabl
use
live
speed
mentor
approach
moder
move
tabl
tabl
facilit
small
group
convers
follow
topic
event
free
limit
particip
regist
select
women
scienc
roundtabl
event
section
regist
icar
lunch
provid
thank
gener
donat
chu
famili
seven
young
women
potenti
make
signific
contribut
field
antivir
research
receiv
chu
famili
foundat
cff
scholarship
year
applic
world
northern
ireland
finland
greec
itali
argentina
hong
kong
spain
australia
unit
state
highli
competit
five
chosen
receiv
scholarship
two
receiv
honorablement
award
scholarship
fund
may
use
attend
confer
visit
laboratori
take
cours
acquir
special
train
award
also
includ
membership
isar
commemor
certif
elig
applic
must
work
area
antivir
research
undergradu
grad
student
five
year
cumul
postdoctor
experi
cff
wi
committe
present
award
icar
mentor
program
launch
icar
raleigh
nc
roundtabl
particip
ask
would
like
mentor
serv
mentor
mente
mentor
match
fill
questionnair
current
interest
career
goal
want
achiev
start
raleigh
program
grew
significantli
th
icar
rome
women
registr
ask
fill
questionnair
meet
wi
committe
match
prospect
mentor
mente
could
first
facetofac
meet
rome
huge
success
mani
new
femal
isar
member
particip
program
definit
buzz
air
mentor
mente
met
first
time
two
year
mentor
match
mente
mentor
usa
belgium
brazil
mente
locat
around
world
includ
germani
nigeria
bulgaria
unit
kingdom
bosnia
herzegovina
netherland
canada
luxembourg
franc
south
korea
india
usa
follow
first
facetofac
meet
mentor
mente
contact
either
email
phone
skype
mentor
provid
career
advic
scientif
expertis
academia
pharmaceut
industri
respons
overwhelmingli
posit
significantli
program
brought
togeth
women
scientist
aspect
antivir
research
differ
stage
career
develop
mani
new
relationship
forg
year
hope
increas
number
mentor
mente
even
attend
previou
roundtabl
pleas
consid
join
mentor
program
mente
mayb
time
becom
mentor
especi
need
mentor
europ
time
zone
mente
interest
join
program
sure
attend
wi
roundtabl
design
meet
place
mentor
mente
look
wi
mentor
program
sign
inform
provid
addit
meet
time
meet
first
let
huge
round
applaus
ami
patick
chair
wi
committe
former
isar
presid
idea
limitless
energi
creat
excit
wi
program
brought
mani
opportun
isar
women
scientist
creativ
passion
left
posit
impact
isar
seen
success
wi
roundtabl
wi
cff
scholarship
mentor
program
ami
soon
pass
torch
one
last
hurrah
la
jolla
remain
activ
member
wi
committe
especi
cff
scholarship
program
conclus
th
icar
rhonda
cardin
becom
wi
chair
rhonda
play
import
role
lead
mentor
program
led
jennif
moffat
karen
buckheit
take
charg
wi
roundtabl
look
new
idea
isar
member
make
event
even
help
women
scientist
final
mani
thank
member
wi
committe
hard
work
dedic
move
forward
icar
held
urabandai
nekoma
hotel
may
meet
jointli
sponsor
japanes
associ
antivir
chemotherapi
shiro
shigeta
fukushima
medic
colleg
lead
local
organ
number
member
jaac
shown
photo
hugh
field
isar
presid
georg
galasso
pastpresid
earl
kern
presidentelect
koen
andri
secretari
jack
secrist
treasur
rich
whitley
chair
program
committe
mike
usseri
joe
colacino
studi
poster
th
icar
joe
confess
still
aw
tie
isar
award
lectur
yet
institut
plenari
present
includ
david
ho
speak
hiv
karen
lindsay
therapeut
trial
hepat
c
akira
matsuda
sah
hydrolas
inhibitor
john
huggin
therapi
emerg
viru
infect
th
icar
held
carib
hilton
hotel
jack
secrist
isar
presid
john
drach
past
presid
chri
mcguigan
presid
elect
ami
patick
secretari
john
morrey
treasur
john
drach
chair
program
committe
elion
award
present
bob
sidwel
gave
lectur
influenza
search
cure
cihlar
receiv
prusoff
young
investig
award
spoke
understand
biolog
attribut
nucleosid
phosphon
first
cidofovir
newest
bob
buckheit
recal
isar
go
financi
thing
cut
back
bare
bone
ran
food
recept
photo
appear
show
member
discuss
possibl
sourc
nutrit
climb
tree
search
coconut
interest
antivir
drug
test
began
student
venezuela
work
aid
lab
nation
institut
hygien
caraca
finish
routin
work
colleagu
would
spend
afternoon
evalu
antivir
activ
larg
collect
compound
extract
natur
product
soon
found
appli
studi
ku
leuven
work
rega
institut
medic
research
guidanc
erik
de
clercq
rega
began
studi
mechan
hiv
entri
focu
intens
research
great
expect
potenti
drug
target
chemokin
identifi
inhibitor
replic
chemokin
receptor
term
fusin
known
coreceptor
hiv
entri
cell
help
explain
hiv
tropism
previous
thought
either
macrophagetrop
tcelltrop
becam
target
drug
use
also
center
current
geneedit
strategi
attempt
cure
hiv
infect
bicyclam
class
entri
inhibitor
elus
mode
action
also
becam
part
research
bicyclam
final
identifi
specif
antagonist
prototyp
becam
market
drug
mobil
stem
cell
also
excel
tool
studi
viruscoreceptor
interact
entri
sinc
time
research
interest
focus
cellular
cofactor
affect
viru
replic
might
use
interven
infect
diseas
work
erik
leuven
also
result
first
contact
isar
attend
icar
first
time
graduat
student
particip
continu
year
never
expect
deepli
involv
manag
societi
complet
phd
studi
join
retrovirolog
laboratori
hospit
german
tria
pujol
badalona
barcelona
later
becom
aid
research
institut
irsicaixa
excit
lead
research
group
rel
earli
stage
career
place
fundament
clinic
research
combin
provid
solut
patient
also
faculti
member
immunolog
program
universitat
de
barcelona
clinic
unit
follow
patient
mani
particip
clinic
trial
collabor
research
time
irsicaixa
wit
hiv
infect
convert
deadli
diseas
poor
treatment
option
manag
chronic
condit
happi
still
see
patient
first
met
year
ago
knowledg
tool
halt
aid
polit
full
access
medicin
educ
need
control
spread
infect
less
fortun
countri
hit
hard
pandem
hiv
infect
treatabl
manag
still
cure
effect
vaccin
nowher
sight
despit
outstand
advanc
deciph
immunolog
pathogenesi
hiv
infect
knowledg
tool
design
effect
prevent
therapeut
vaccin
still
avail
includ
unambigu
identif
adequ
surrog
marker
protect
evalu
efficaci
hiv
vaccin
therefor
requir
long
costli
clinic
trial
glimps
potenti
use
howev
cautiou
optim
regard
earli
clinic
develop
number
vaccin
candid
broadli
neutral
antibodi
field
come
realiz
without
vaccin
wo
nt
end
hiv
lab
current
line
research
attempt
understand
hostpathogen
interact
hiv
cofactor
affect
viru
replic
cellular
mechan
affect
viru
persist
hiv
integr
cellular
genom
cell
may
becom
latent
infect
life
antiretrovir
treatment
interrupt
reason
viremia
rebound
within
day
treatment
need
resum
hiv
reactiv
subject
intens
research
worldwid
perceiv
strategi
purg
latent
infect
cell
even
though
strategi
may
eventu
prove
wrong
certainli
repres
basi
futur
effect
treatment
aim
erad
hiv
bodi
cellular
protein
function
triphosphohydrolas
reduc
intracellular
titer
dntp
requir
dna
synthesi
cell
prolifer
revers
transcript
mutat
associ
aberr
dna
synthesi
autoimmun
diseas
permiss
group
recent
identifi
biochem
pathway
lead
activ
deactiv
host
factor
restrict
infect
nonprolifer
cell
monocyt
macrophag
dendrit
cell
intracellular
restrict
hiv
replic
appear
tightli
depend
control
cell
cycl
precis
orchestr
system
allow
cell
prolifer
deviat
lead
either
aberr
cell
prolifer
cancer
dna
damag
apoptosi
cell
death
cell
prolifer
also
tightli
link
cell
detect
incom
pathogen
trigger
innat
antivir
respons
thu
system
cellular
checkpoint
control
dna
replic
transcript
may
provid
basi
understand
innat
immun
hiv
infect
proviru
awaken
transcrib
importantli
cell
prolifer
affect
persist
hiv
exampl
homeostat
cell
prolifer
infect
cell
begin
explor
drug
target
cell
cycl
cell
prolifer
may
use
interven
hiv
replic
latenc
block
expans
infect
cell
recent
identif
provir
dna
integr
gene
associ
cancer
cellcycl
regul
observ
regul
appear
serv
import
mechan
viral
persist
may
indic
therapi
target
hivinfect
prolifer
cell
may
implement
cure
hiv
infect
isar
meant
lot
scientif
career
mani
time
confer
serv
perfect
platform
convey
discuss
group
research
effect
seek
collabor
other
learnt
great
deal
drug
develop
close
collabor
academia
industri
requir
bring
new
drug
closer
patient
time
mani
complementari
scientif
meet
occur
simultan
technolog
brought
us
closer
togeth
icar
still
repres
excel
platform
characterist
multidisciplinari
compon
stand
meet
focus
virolog
drug
develop
medic
scienc
provid
perfect
stage
student
young
research
come
contact
scientist
stakehold
identifi
character
develop
new
antivir
agent
way
draw
board
bench
clinic
isar
make
great
effort
support
encourag
particip
young
research
invit
becom
involv
societi
receiv
william
prusoff
young
investig
award
member
isar
board
director
number
year
elect
presidentelect
term
presid
begin
end
meet
la
jolla
prepar
take
lead
role
feel
indebt
isar
recent
reelect
isar
execut
board
second
term
kathi
societi
member
sinc
earli
serv
chair
poster
award
past
four
year
current
professor
chemistri
biochemistri
univers
maryland
baltimor
counti
umbc
umbc
presidenti
research
professor
also
presid
intern
societi
nucleosid
nucleotid
nucleic
acid
seem
like
alway
love
scienc
grow
eri
pa
combin
high
schoolcolleg
program
genet
found
attract
first
research
project
bought
two
blackandwhitespot
mice
pet
shop
bred
produc
pure
black
strain
took
year
half
one
point
mice
bedroom
drove
parent
cat
crazi
eventu
interest
shift
mice
chemistri
two
wonder
organ
chemistri
professor
st
petersburg
colleg
clearwat
florida
year
later
found
gravit
toward
medicin
chemistri
want
someth
appli
chanc
spend
life
look
way
cure
diseas
excit
stew
schneller
chair
chemistri
depart
univers
south
florida
join
lab
graduat
student
initi
project
focus
synthes
cyclobutyl
nucleosid
relat
lobucavir
goal
inhibit
hepat
b
viru
two
year
phd
stew
move
auburn
univers
becom
dean
move
auburn
finish
research
work
seri
carbocycl
nucleosid
specif
unnatur
llike
nucleosid
receiv
phd
auburn
stay
stew
postdoc
anoth
two
year
continu
focu
design
synthesi
carbocycl
nucleosid
analogu
antivir
time
especi
interest
inhibit
sadenosylhomocystein
hydrolas
way
shut
viral
parasit
replic
pathway
compound
screen
mani
virus
often
chang
target
base
result
drug
screen
work
brought
contact
mani
longterm
collabor
rega
institut
includ
erik
de
clercq
jan
balzarini
johan
neyt
graciela
andrei
robert
snoeck
liev
naesen
also
research
institut
includ
brent
korba
earl
kern
dale
barnard
remain
good
friend
left
stew
group
begin
independ
career
georgia
tech
continu
work
carbocycl
also
decid
expand
scope
project
potenti
viral
target
landscap
primari
focu
turn
design
synthesi
ribos
nucleosid
analogu
one
first
nihfund
project
center
seri
nucleosid
expand
purin
extend
pyrimidin
nucleobas
relat
nelson
leonard
expand
linbenzoadenosin
analogu
basic
chemistri
main
prioriti
remain
develop
novel
antivir
expand
purin
project
flexim
lab
known
ultim
evolv
sinc
seen
success
structur
uniqu
nucleosid
number
virus
even
parasit
sinc
join
umbc
primari
focu
synthesi
character
variou
class
flexibl
nucleosid
shown
figur
molecul
split
purin
heterocycl
base
permit
turn
rotat
remain
connect
singl
carboncarbon
bond
therefor
retain
key
featur
need
hydrogenbond
basepair
also
abl
reposit
within
enzym
bind
site
face
steric
electron
clash
viral
drug
resist
often
develop
point
mutat
enzym
bindingsit
flexim
possess
advantag
convent
rigid
nucleosid
analogu
structur
divers
nucleosid
upper
left
thiopheneexpand
purin
analogu
show
activ
hcv
upper
right
flexg
first
guanosin
analogu
report
inhibit
sadenosylhomocystein
hydrolas
adenosin
metabol
enzym
bottom
doubl
prodrug
flexacyclovir
first
nucleosid
analogu
report
exhibit
potent
activ
coronavirus
specif
merscov
team
umbc
pursu
sever
differ
type
flexim
variou
modifi
sugar
includ
seri
analogu
relat
sofosbuvir
gemcitabin
well
carbocycl
flexim
analogu
molecul
inhibit
varieti
virus
parasit
primari
focu
recent
develop
doublyflex
analogu
potent
activ
coronavirus
last
year
publish
first
report
nucleosid
analogu
flexacyclovir
inhibit
mer
coronaviru
soon
report
recent
result
addit
analogu
exhibit
even
better
select
potenc
meantim
colleagu
leuven
leiden
screen
sever
prodrug
doubl
flexim
correspond
triphosph
flexacyclovir
enter
test
well
also
synthes
second
seri
doublyflex
analogu
base
tenofovir
relat
project
collabor
sina
bavari
veronica
soloveva
usamriid
sam
lee
doug
mayer
other
cocryst
develop
antivir
ebola
viru
hope
report
result
project
come
month
well
third
project
center
around
disrupt
proteinprotein
interact
hiv
nucleocapsid
protein
flexbas
analogu
term
heterocyl
base
inhibitor
also
work
close
two
group
russia
collabor
mikhail
novikov
volgograd
medic
univers
uncov
number
potent
nonnucleosid
inhibitor
variou
virus
date
back
first
project
georgia
tech
involv
expand
purin
extend
pyrimidin
eight
year
ago
one
grad
student
kartik
temburnikar
assign
tackl
extend
pyrimidin
part
project
seri
cnucleosid
thienoand
pyrrolopyrimidin
base
interestingli
made
thiopheneexpand
purin
base
back
exhibit
anticanc
activ
got
buri
excit
flexim
project
somewhat
forgotten
kartik
came
across
paper
four
year
ago
decid
send
nucleobas
nucleosid
screen
thank
good
make
long
stori
short
jan
balzarini
tox
studi
gave
us
first
clue
compound
might
valu
cancer
screen
nci
reveal
lownanomolar
activ
number
import
cancer
umb
collabor
observ
tumor
shrinkag
day
mous
melanoma
xenograft
model
toxic
unlik
temozolomid
standard
care
fairli
toxic
result
screen
cancer
recent
obtain
fund
test
compound
anim
target
leukemia
nonsmallcel
lung
pancreat
tripleneg
breast
cancer
encourag
compound
may
provid
cheaper
altern
expens
drug
recruit
depart
defens
collabor
smallpox
research
russian
scientist
part
cooper
threat
reduct
program
start
go
russia
sever
time
year
select
jefferson
scienc
fellow
nation
academi
scienc
spent
year
state
depart
washington
work
former
weapon
scientist
well
russian
virologist
chemist
project
emerg
reemerg
infecti
diseas
effort
focus
us
nonprolifer
effort
prevent
use
biolog
pathogen
biowarfar
bioterror
spent
lot
time
russia
also
indonesia
follow
time
state
depart
went
back
russia
sever
month
year
help
variou
scientif
issu
us
embassi
moscow
includ
everchang
polit
landscap
scientist
russia
succeed
establish
sever
research
collabor
continu
today
one
reward
aspect
scienc
opportun
cross
scientif
disciplin
intern
border
medicin
chemist
extrem
fortun
work
close
excel
collabor
mani
met
isar
addit
mention
coronaviru
project
group
collabor
johan
neyt
dirk
jochman
leuven
recent
eric
snijder
adriaan
de
wild
clara
posthuma
leiden
medic
univers
netherland
johan
dirk
first
discov
compound
anticoronaviru
activ
introduc
eric
group
see
articl
last
isar
news
discuss
work
coronavirus
includ
merscov
result
flexacyclovir
relat
analogu
needless
say
excit
find
doubli
flexibl
nucleosid
one
exampl
shown
bottom
figur
still
cure
sar
mer
given
outbreak
last
year
south
korea
find
nucleosid
success
evad
rather
vigil
coronaviru
proofread
mechan
groundbreak
recent
file
joint
patent
novel
approach
look
forward
pursu
excit
lead
bring
full
circl
isar
definit
play
key
role
success
look
forward
icar
year
excel
opportun
see
old
friend
catch
groundbreak
result
cours
meet
face
face
collabor
mind
determin
first
crystal
structur
coronaviru
protein
pro
transmiss
gastroenter
viru
tgev
porcin
coronaviru
structur
reveal
novel
helic
domain
addit
classic
chymotrypsinfold
necess
dimer
format
catalyt
activ
motiv
us
synthes
simpl
chloromethylketon
inhibitor
sar
epidem
publish
second
coronaviru
structur
pro
human
coronaviru
well
homolog
model
correspond
sarscov
enzym
basi
structur
tgev
pro
complex
chloromethylketon
inhibitor
dock
experi
propos
rupintrivir
develop
time
pfizer
inhibitor
rhinoviru
proteas
would
nearli
fit
substratebind
site
sarscov
pro
could
therefor
start
point
design
antisar
drug
predict
verifi
littl
later
rupintrivir
inact
sar
cov
deriv
michael
acceptor
compound
lack
pfluorobenzyl
group
posit
potent
inhibitor
subsequ
onlin
public
paper
scienc
invit
chines
govern
come
beij
emerg
meet
peak
sar
epidem
case
citi
event
met
zihe
rao
invit
stay
tsinghua
univers
work
crystal
structur
sarscov
pro
publish
month
later
three
pro
structur
laid
cornerston
design
antivir
drug
coronavirus
use
mani
research
purpos
year
follow
sar
outbreak
mani
structur
coronaviru
protein
determin
mainli
group
zihe
rao
beij
peter
kuhn
ray
steven
kurt
san
diego
bruno
canard
marseil
group
focus
nonstructur
protein
nsp
encod
open
read
frame
particular
x
domain
sarsuniqu
domain
unfortun
goal
anticoronaviru
drug
design
got
bit
lost
rush
new
structur
one
reason
fund
research
sar
cov
declin
rapidli
mani
countri
partli
fault
virolog
commun
mani
colleagu
believ
sar
epidem
onetim
event
would
never
repeat
structur
sar
cov
main
proteas
continu
design
synthes
peptid
aldehyd
nonpeptid
benzotriazol
inhibitor
sarscov
pro
even
group
start
chang
focu
target
enteroviru
proteas
creat
peptidomimet
michael
acceptor
compound
superb
activ
cell
cultur
enteroviru
ev
caus
agent
summer
flu
hit
midwest
usa
viru
caus
hand
foot
mouth
diseas
human
rhinovirus
reactiv
antivir
design
effort
coronavir
pro
merscov
surfac
late
recogn
thousand
case
sever
cov
diseas
would
never
make
develop
antivir
drug
commerci
viabl
seriou
enteroviru
infect
far
common
aim
design
inhibitor
would
nearli
equipot
enterovirus
betacoronavirus
sarscov
merscov
alphacoronavirus
hcov
howev
goal
difficult
reach
challeng
target
alphacoronaviru
pro
far
smaller
less
flexibl
pocket
correspond
proteas
enterovirus
betacoronavirus
cours
studi
synthes
dozen
compound
determin
quit
number
crystal
structur
final
found
alphaketoamid
fulfil
design
goal
remark
potent
molecul
ec
nm
merscov
liver
cell
addit
cov
main
proteas
also
becam
interest
polyproteinprocess
enzym
coronavirus
papainlik
proteas
determin
would
enthusiast
share
experi
sightse
recommend
last
convers
hour
death
kri
affection
care
person
met
year
ago
still
enthusiast
hepat
research
recent
advanc
field
grate
long
associ
especi
guidanc
earli
year
career
long
relationship
friend
colleagu
also
cherish
friendship
love
hospit
wife
elzbieta
miss
much
saleem
kamili
phd
act
branch
chief
laboratori
branch
divis
viral
hepat
cdc
atlanta
ga
kathi
seleyradtk
would
like
isar
member
know
xxii
intern
round
tabl
nucleosid
nucleotid
nucleic
acid
held
juli
institut
pasteur
pari
meet
organ
research
institut
pasteur
parisdescart
collabor
intern
societi
nucleosid
nucleotid
nucleic
acid
http
irt
held
everi
year
bring
togeth
chemist
molecular
biologist
biochemist
biologist
medicin
chemist
interest
understand
aspect
field
topic
pari
meet
includ
approv
drug
bench
bedsid
anticanc
antiinfect
biolog
activ
nucleo
ide
innovationdriven
nucleo
ide
chemistri
nucleotid
signal
molecul
synthesi
structur
nucleic
acid
oligonucleotid
therapeut
applic
biotechnolog
biochemistri
nucleosid
nucleic
acid
xxii
irt
aim
put
forefront
latest
develop
innovationdriven
nucleosid
nucleotid
oligonucleotid
chemistri
academia
industri
deal
new
challeng
centuri
deadlin
abstract
submiss
april
th
inform
go
meet
websit
http
contact
kathi
seleyradtk
presid
advanc
studi
week
arbovirus
take
place
praia
tofo
inhamban
mozambiqu
aug
confer
organ
isar
member
rolf
hilgenfeld
univers
germani
subhash
vasudevan
duken
univers
singapor
collabor
dr
eduardo
samo
gudo
scientif
director
nation
institut
health
mozambiqu
studi
week
focu
princip
dengu
zika
chikungunya
virus
arbovirus
west
nile
japanes
enceph
includ
follow
scientif
session
plan
dengu
west
nile
zika
chikungunya
outbreak
past
present
molecular
biolog
flaviand
alphavirus
differenti
diagnost
vaccin
develop
antivir
drug
vector
control
public
health
issu
outbreak
respons
encourag
discuss
scientif
interact
meet
limit
particip
alloc
firstcom
firstserv
basi
event
take
place
tofo
del
mar
newli
renov
hotel
situat
directli
beauti
indian
ocean
beach
tofo
km
inhamban
airport
flight
maputo
mozambiqu
johannesburg
south
africa
addit
inform
http
wwwemergingvirusesorg
meet
build
success
advanc
studi
week
ebola
filovirus
held
tofo
see
wwwebolaconferenceorg
europ
seri
everyotheryear
intern
confer
picornavirus
sponsor
european
studi
group
molecular
biolog
picornavirus
first
meet
held
enkhuizen
netherland
th
europ
take
place
le
diableret
switzerland
septemb
topic
rang
hepat
polio
footandmouth
diseas
session
focus
viru
life
cycl
viral
genet
erad
strategi
antivir
therapi
topic
eckard
wimmer
give
open
keynot
lectur
johan
neyt
chair
session
antivir
inform
contact
johan
go
mike
bray
editorinchief
antivir
research
would
like
isar
member
know
avr
sponsor
enzo
tramontano
would
like
inform
isar
member
meet
innov
approach
identif
novel
antivir
agent
held
cagliari
septemb
summer
school
design
provid
graduat
student
postdoctor
fellow
opportun
interact
intern
recogn
expert
antivir
field
critic
review
scientif
literatur
share
idea
discuss
new
paradigm
futur
investig
day
confer
consist
morn
seri
plenari
lectur
afternoon
small
themat
discuss
group
even
present
young
scientist
research
